Canary Speech Announces New Patent for Its Technology in Using Voice to Detect Medical Conditions
Canary Speech, a speech and language company known for identifying disease and human conditions through the creation of mathematical models to identify biomarkers from a limited vocal sample, announced that the U.S. Patent and Trademark Office has granted to Canary Speech a patent for broader claims for its inventions.
The patent is titled, Selecting Speech Features For Building Models For Detecting Medical Conditions (US-2018-0322894-A1). The patent covers Canary Speech's innovative technology that leverages AI and machine learning to build voice models to identify medical conditions and cognitive diseases. Canary Speech has developed HIPAA-compliant tools that have been used in FDA and IRB medical research and clinical drug trials.
Canary Speech is a speech and language technology company based in Provo, Utah. The company focuses on the classification of disease and human condition through speech and language with the use of AI and machine learning. Speech and language models are developed with proprietary and patented technology creating specific disease and human condition related algorithms. These models can be used in pharmaceutical / FDA drug trials as an objective measurement of a drug's efficacy. It is anticipated that the models will also be used in the diagnosis and assessment of disease and various medical conditions, as well as early screening for cognitive decline, Alzheimer's disease, Parkinson's, depression, stress and the like. Canary Speech is currently working with companies in both North America and Japan.
Constant Companion and Canary Speech study to explore how voice and AI technologies can detect conditions such as anxiety, depression, and Alzheimer's.
The strategic purchase enhances the company's cloud communications services with intellectual property that helps users remember, retrieve, and record everything that happens on a phone call.